The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent ...

North Carolina-based CRO Fortrea is saying goodbye to its CEO. | North Carolina-based CRO Fortrea is saying goodbye to its ...

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...